Phaseline

Targets › LMP2A

LMP2A: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jul 2031.

Open in Phaseline: the race on LMP2A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Baylor College of MedicineTGFbeta resistant LMP-specific CTLs
TGF-beta-resistant, LMP2A-specific cytotoxic T lymphocytes engineered to target EBV-associ
LMP2APhase 1LymphomaJul 2031

Conditions

Lymphoma (1)

Modalities

protein or peptide (1)

Companies

Baylor College of Medicine (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.